MCID: LNG064
MIFTS: 32

Lung Cancer Susceptibility 3 malady

Genetic diseases, Rare diseases, Respiratory diseases, Cancer diseases categories

Aliases & Classifications for Lung Cancer Susceptibility 3

About this section

Aliases & Descriptions for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 46 9 61
Lung Adenocarcinoma 30 8 42
Adenocarcinoma of Lung 42 61
 
Non-Small Cell Adenocarcinoma 61
Nonsmall Cell Adenocarcinoma 8
Adenocarcinoma Lung 44


Classifications:



External Ids:

OMIM46 612571
Disease Ontology8 DOID:3910
SNOMED-CT56 254626006
MeSH33 C538231
NCIt39 C3512

Summaries for Lung Cancer Susceptibility 3

About this section
Disease Ontology:8 A non-small cell lung carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Lung Cancer Susceptibility 3, also known as lung adenocarcinoma, is related to adenocarcinoma and lung cancer. An important gene associated with Lung Cancer Susceptibility 3 is LNCR3 (Lung cancer susceptibility 3). Affiliated tissues include lung, skeletal muscle and endothelial.

Description from OMIM:46 612571

Related Diseases for Lung Cancer Susceptibility 3

About this section

Diseases in the Lung Cancer Susceptibility 2 family:

Lung Cancer Susceptibility 5 lung cancer susceptibility 3
Lung Cancer Susceptibility 4

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 119)
idRelated DiseaseScoreTop Affiliating Genes
1adenocarcinoma11.6
2lung cancer10.6
3hypoxia10.6
4mesothelioma10.6
5endotheliitis10.5
6thyroiditis10.5
7adenocarcinoma in situ10.4
8li-fraumeni syndrome10.3
9paraneoplastic syndromes10.3
10obstructive jaundice10.3
11esophagitis10.3
12meningitis10.3
13sarcoma10.3
14colorectal cancer10.2
15newcastle disease10.2
16bronchogenic lung adenocarcinoma10.2
17interstitial lung disease10.2
18pneumothorax10.2
19breast cancer10.1
20tumor predisposition syndrome10.1
21b-cell lymphomas10.1
22neuroendocrine carcinoma10.1
23actinomycosis10.1
24adenoiditis10.1
25choroiditis10.1
26lambert-eaton myasthenic syndrome10.1
27dermatomyositis10.1
28lung squamous cell carcinoma10.1
29melanoma10.1
30pancreatitis10.1
31pericardial effusion10.1
32prostatitis10.1
33papillary adenocarcinoma10.0
34polymorphous low-grade adenocarcinoma10.0
35rhabdoid tumor10.0
36rheumatoid arthritis10.0
37prostate cancer10.0
38hepatocellular carcinoma10.0
39optic atrophy 110.0
40ataxia-telangiectasia10.0
41aspergillosis10.0
42retinoblastoma10.0
43ataxia-telangiectasia-like disorder10.0
44xeroderma pigmentosum, group c10.0
45cervical cancer, somatic10.0
46anaplastic large cell lymphoma10.0
47chromophobe renal cell carcinoma10.0
48focal segmental glomerulosclerosis10.0
49hydrocephalus10.0
50marginal zone b-cell lymphoma10.0

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to lung cancer susceptibility 3

Symptoms for Lung Cancer Susceptibility 3

About this section


Clinical features from OMIM:

612571

Drugs & Therapeutics for Lung Cancer Susceptibility 3

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Gilotrif13 38 AFATINIB DIMALEATE Boehringer Ingelheim Approved July 2013
FDA Label: Gilotrif
Malady that Drug Treats: metastatic non-small cell lung cancer with EGFR mutations
Indications and Usage:13 GILOTRIF is a kinase inhibitor indicated for the first-line treatment of; patients with metastatic non-small cell lung cancer (NSCLC) whose tumors; have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21; (L858R) substitution mutations as detected by an FDA-approved test (1); Limitation of Use: Safety and efficacy of GILOTRIF have not been; established in patients whose tumors have other EGFR mutations (1)
DrugBank Targets:11 1. Epidermal growth factor receptor; 2. Receptor tyrosine-protein kinase erbB-2; 3. Receptor tyrosine-protein kinase erbB-4
Mechanism of Action:13 
Target: tyrosine kinase autophosphorylation
Action: inhibitor
FDA: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and; irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling.; Afatinib demonstrated inhibition of autophosphorylation and in vitro proliferation of cell lines expressing wildtype; EGFR or those expressing selected EGFR exon 19 deletion mutations or exon 21 L858R mutations,; including some with a secondary T790M mutation, at afatinib concentrations achieved, at least transiently, in; patients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2.; Treatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors either; overexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model.

Drug clinical trials:

Search ClinicalTrials for Lung Cancer Susceptibility 3

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Genetic Tests for Lung Cancer Susceptibility 3

About this section

Anatomical Context for Lung Cancer Susceptibility 3

About this section

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

31
Lung, Skeletal muscle, Endothelial, Cortex, Pancreas, Myeloid, B cells, Pituitary

Animal Models for Lung Cancer Susceptibility 3 or affiliated genes

About this section

Publications for Lung Cancer Susceptibility 3

About this section

Variations for Lung Cancer Susceptibility 3

About this section

Expression for genes affiliated with Lung Cancer Susceptibility 3

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 30 (show all 15)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1COL11A1collagen, type XI, alpha 1Lung+5.070.000
2MMP1matrix metallopeptidase 1 (interstitial collagenase)Lung+4.750.000
3CDH3cadherin 3, type 1, P-cadherin (placental)Lung+4.310.000
4SPP1secreted phosphoprotein 1Lung+4.040.000
5SPINK1serine peptidase inhibitor, Kazal type 1Lung+3.960.000
6COL10A1collagen, type X, alpha 1Lung+3.790.000
7TMPRSS4transmembrane protease, serine 4Lung+3.530.000
8ABCC3ATP-binding cassette, sub-family C (CFTR/MRP), member 3Lung+3.470.000
9TOP2Atopoisomerase (DNA) II alpha 170kDaLung+3.410.000
10GINS2GINS complex subunit 2 (Psf2 homolog)Lung+3.290.000
11NEK2NIMA-related kinase 2Lung+3.270.000
12TOX3TOX high mobility group box family member 3Lung+3.240.000
13CRABP2cellular retinoic acid binding protein 2Lung+3.110.000
14COL1A1collagen, type I, alpha 1Lung+3.050.000
15NMUneuromedin ULung+3.050.000

Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.

Pathways for genes affiliated with Lung Cancer Susceptibility 3

About this section

Compounds for genes affiliated with Lung Cancer Susceptibility 3

About this section

GO Terms for genes affiliated with Lung Cancer Susceptibility 3

About this section

Sources for Lung Cancer Susceptibility 3

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet